Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN- γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients.
Conclusion: PBMCs from RA patients are responsive in inhibiting proinflammatory cytokines using Losartan better than Enalapril and Valsartan and it could be a better antihypertensive choice for patients with RA and systemic arterial hypertension treatment.
PMID: 30288187 [PubMed]
Source: Open Rheumatology Journal - Category: Rheumatology Tags: Open Rheumatol J Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Cozaar | Diovan | Enalapril | Heart | Hypertension | Laboratory Medicine | Losartan | Rheumatoid Arthritis | Rheumatology